Sandoz Group AG is a global leader in the development, manufacturing, and marketing of generic and biosimilar medicines, spun off from Novartis in 2023. The company holds a prominent position in generic antibiotics, supported by a vertically integrated penicillin network in Europe, and pioneered the biosimilar market.

Sandoz benefits from its deep pipeline covering approximately 59% of upcoming biologics loss of exclusivity (LOE) and 65% of small molecule LOE over the next decade. Its substantial investment in vertical integration, including a $1.1B expansion of its European biosimilar hub in Slovenia, provides strong supply chain control and cost advantages.

• 2026-08-05: Q2 2026 sales acceleration was driven by the successful June 2025 launches of Wyost and Jubbonti in North America, which captured 54% and 64% of the biosimilar market respectively.
• 2026-07-22: Proposed U.S. generic tariffs highlight manufacturing exposure, as the U.S. accounts for ~17% of group sales while Sandoz's footprint is predominantly European. Management is in active dialogue with the U.S. administration.
• 2026-06-29: FDA accepted two applications for generic versions of tirzepatide (Eli Lilly's Zepbound/Mounjaro), positioning Sandoz as a potential first-to-market generic entrant upon patent expiry.
• 2026: Reached a settlement to resolve all pending class actions and governmental claims in legacy U.S. generic antitrust litigation involving $400M spread over 7 years, removing a significant overhang.

• ⚠️ Proposed U.S. generic tariffs could weigh on profitability given Sandoz's reliance on its European manufacturing hub.
• Pipeline execution remains a major risk, where any delay to product launches could affect future growth.
• Intense competition and continuous pricing pressure in the generics market.